Google
TWST Stock Analysis — TWIST BIOSCIENCE CORP (Healthcare >> Diagnostics & Research)
TWST FAQ
What is TWST's P/E ratio?
TWIST BIOSCIENCE CORP (TWST) currently trades at a P/E ratio of 278.92.
What is TWST's ROE?
TWIST BIOSCIENCE CORP reports a Return on Equity (ROE) of -17.86%.
What is TWST's dividend yield?
TWIST BIOSCIENCE CORP offers a dividend yield of 0.00%.
What is TWST's Quality Score?
Our AI rates TWST's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TWST?
Our AI Timing Score for TWST is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TWST belong to?
TWIST BIOSCIENCE CORP is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
TWST AI Analysis Summary
Our AI summary for TWST: TWIST BIOSCIENCE CORP (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 278.92, ROE of -17.86%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 91.55
Price
0.22
(0.24%)
Day Change
|
|
|---|
TWST, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 91.55 |
| PBV / Sector |
12.50 / -29.69
|
| Earning Per Share | -1.31 |
| PE / Sector |
278.92 / 48.18
|
| PEG or PE/Growth / Sector |
-11.17 / 1.64
|
| Average 1M Daily Value |
121.89 M
GREAT
|
| Average 1W Daily Value |
129.86 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:37 |
| Symbol | TWST |
| Name | TWIST BIOSCIENCE CORP |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 62.27 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,687.24 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 681 Gateway Boulevard, South San Francisco, CA, United States, 94080
Phone: 800 719 0671
Website: https://www.twistbioscience.com
Employees: 979
Description: Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
